News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Delayed Nyse Other stock markets 04:01:04 2023-09-27 pm EDT			5-day change	1st Jan Change
103.94 ^USD	-1.38%		-3.14%	-6.32%

Sep. 25	Merck's COVID Drug Lagevrio Linked to Virus Mutation Patterns, Study Says	MT
Sep. 22	Hawkish Remarks by Fed Officials Weigh on Equity Markets	MT

Summary

Merck's COVID Drug Lagevrio Linked to Virus Mutation Patterns, Study Says	Sep. 25	MT
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients with Certain Types of Metastatic Non-Small Cell Lung Cancer	Sep. 25	AQ
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival in Certain Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer	Sep. 25	AQ
Hawkish Remarks by Fed Officials Weigh on Equity Markets	Sep. 22	MT
Sector Update: Health Care	Sep. 22	MT
Global markets live: GM, Ford, Stellantis, Microsoft, McDonald's...	Sep. 22
Merck & Co. Lung Cancer Combo Trials Fail to Meet Endpoints	Sep. 22	MT
September lives up to its reputation	Sep. 22
Sector Update: Health Care	Sep. 22	MT
Merck & Co.’s Bladder Cancer Combo Meets Primary Endpoints in Late-stage Trial	Sep. 22	MT
Merck, Eisai Say Two Phase 3 Keytruda-Lenvima Trials for Lung Cancer Did Not Meet Endpoints	Sep. 22	MT
Seagen, Astellas Pharma, Merck Say Phase 3 Trial of Bladder Cancer Combination Therapy Met Endpoints	Sep. 22	MT
Merck, Eisai: Keytruda/Lenvima Combo Fails in Two Non-Small Cell Lung Cancer Studies	Sep. 22	DJ
Merck says Keytruda combination fails in lung cancer trial	Sep. 22	RE
Merck, Seagen, Astellas Phase 3 Bladder Cancer Study Hits Endpoints	Sep. 22	DJ
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer	Sep. 22	BU
Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer	Sep. 22	CI
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer	Sep. 22	BU
Merck & Co., Inc. Announces Phase 3 Keynote-A39/Ev-302 Trial Met Dual Primary Endpoints of Overall Survival (Os) and Progression-Free Survival in Certain Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer	Sep. 22	CI
FDA Grants Priority Review to Merck's Application for KEYTRUDA plus Concurrent Chemoradiotherapy as Treatment for Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer	Sep. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features

News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Summary

Filters